Drug Profile
Lumasiran - Alnylam Pharmaceuticals
Alternative Names: ALN-GO1; Lumasiran; OxlumoLatest Information Update: 27 Feb 2024
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Class Amino sugars; Drug conjugates; Small interfering RNA; Uricosurics; Urologics
- Mechanism of Action Glycolate oxidase expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Primary hyperoxaluria type 1
- Phase II Urinary calculi
Most Recent Events
- 27 Feb 2024 Registered for Primary hyperoxaluria type 1 in Qatar (SC) (Prior to February 2024)
- 12 Jan 2024 Alnylam Pharmaceuticals completes the phase III ILLUMINATE-A trial for Primary hyperoxaluria type 1 (In adolescents, In children, In adults, In the elderly) in USA, France, Germany, Israel, Netherlands, Switzerland, United Arab Emirates and United Kingdom (NCT03681184)
- 28 Apr 2023 Efficacy and adverse events data from a phase III ILLUMINATE-A trial in Primary hyperoxaluria type 1 presented at the 118th Annual Meeting of the American Urological Association (AUA-2023)